Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The role of real-world data in value-based assessment of cancer drugs

A new editorial discusses the role of real-word data against a background of increasingly intense discussion on pricing and affordability of new cancer drugs, the responsible behaviour of pharmaceutical companies, and the lack of transparency in pricing and R&D expenditure.

The authors, Wim van Harten and Maarten J IJzerman, from the The Netherlands Cancer Institute, University Twente, European Organization of Cancer Institutes, Rijnstate Hospital, and the Luxembourg Institute of Health, explain that Real-World Evidence (RWE) may play a pivotal role in developing sustainable cancer care, because it allows much better estimates of actual drug use and costs and increases transparency in health outcomes.

Read the full editorial here.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation